ライフサイエンスコーパス: gene signature

1 low-risk or high-risk groups based on the 52-gene signature.

2 the presence or absence of a T-cell-inflamed gene signature.

3 C3KO muscles fail to activate the same gene signature.

4 rexpression of a type-I interferon signaling gene signature.

5 17 unique protein-coding genes yielding a 17-gene signature.

6 , and patients with a potentially predictive gene signature.

7 ated with SRC expression and a SRC-dependent gene signature.

8 with an epithelial-to-mesenchymal transition gene signature.

9 lico that could reverse the COPD lung tissue gene signature.

10 y those with an elevated baseline type I IFN gene signature.

11 RB-E2F pathway in regulating the prognostic gene signature.

12 e to derive a spatially informed, prognostic gene signature.

13 ide and defined an early dorsal beta-catenin gene signature.

14 factors and hypoxia-inducible-factor (HIF)-1 gene signature.

15 agents to reverse beta-defensin 1-associated gene signature.

16 ized procedure for constructing high quality gene signatures.

17 ated IRF3 and induction of MAVS and IFN-beta gene signatures.

18 profiling followed by deconvolution of their gene signatures.

19 l phases are characterized by distinct blood gene signatures.

20 levels displayed correlated low canonical AR gene signatures.

21 sis revealed marked differences in metabolic gene signatures.

22 e set analysis using data-defined functional gene signatures.

23 clinically relevant invasion and metastasis gene signatures.

24 ypes of intestinal epithelial cell and their gene signatures.

25 as inversely connected to the breast cancer gene signatures, 14 of them are known anti-cancer drugs.

26 Eight cancer hallmark-based gene signatures (30 genes each) were identified and used

27 We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients

28 sion of epithelial-to-mesenchymal transition gene signature, a feature of invasive and metastatic can

29 To validate the robustness of the gene signature, a meta-analysis approach was applied to

30 In a previous work we identified a five-gene signature able to distinguish intracranially BSE-in

31 ring an epithelial ovarian cancer prognostic gene signature across technologies, from a microarray to

32 (BL) and high-grade B-cell lymphoma with BL gene signature (adult-molecularly defined BL [mBL]) reve

33 ed a glycolytic and tricarboxylic acid cycle gene signature, alongside increased glucose uptake and a

34 This 25-gene signature also defined basal IFN activation states

35 onarily conserved because early NKT and IL-4 gene signatures also positively correlate with the level

36 These findings are corroborated by gene signature analysis, which demonstrates that basal o

37 ch patient based on the expression of the 17-gene signature and a significant increasing trend in the

38 memory Tfh cells exhibit an IL-2-responsive gene signature and are more polarized toward a Th1 pheno

39 er and activator of transcription (IFN/STAT) gene signature and are often enriched for cancer stem ce

40 impaired, causing up-regulation of a TGFbeta gene signature and elevated hepatocyte growth factor (HG

41 Parainflammation can be identified from a 40-gene signature and is found in both carcinoma cell lines

42 udy is to gain improved understanding of the gene signature and molecular pathways regulating the pro

43 This remodeling produces a distinct gene signature and new vulnerabilities to the proapoptot

44 hat hnRNPF negatively correlates with an EMT gene signature and positively correlates with patient su

45 is shown to be associated with a lipogenesis gene signature and specific induction of fatty acid synt

46 NK cells unexpectedly acquired an ILC1-like gene signature and were unable to control tumor metastas

47 The aging gene signatures and complex disease genes show a complex

48 However, how inflammatory gene signatures and cREL/p63/p73 targets are comodulated

49 Induced FOXA1 triggers oncogenic gene signatures and proteomic profiles highly associated

50 iology of disease on the basis of microarray gene signatures and reduction strategies.

51 between sIgG/sIgE ratios and IL-10-dependent gene signatures and significantly higher IL-10/TH2 cytok

52 We report on East-Asian alpha- and beta-cell gene signatures and substantiate several genes/pathways.

53 determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modifie

54 und to be highly associated with a mast cell gene signature, and accordingly, mouse MPNST-like melano

55 hes a PGE2- and COX2-mediated wound response gene signature, and attenuates progressive manifestation

56 , cytolytic capacity, expression of stemness gene signature, and decreased TGF-beta signaling.

57 ssion levels strongly correlate with an MDSC gene signature, and high expression of YAP or MDSC-relat

58 lungs of IC animals revealed a prominent M2 gene signature, and these macrophages effectively elicit

59 curately identifies individual gene targets, gene signatures, and cell states affected by individual

60 itively associate with TWIST1/2 and EMT-like gene signatures, and miR-424 is increased in primary tum

61 ating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry.

62 2) the identification of cell type specific gene signatures; and 3) the determination of driving for

63 Here we have established an HCC risk gene signature applicable to all major HCC etiologies: h

64 expressed genes, biological conclusions, and gene signatures are highly concordant between two techni

65 Annotated gene sets (referred to as gene 'signatures') are incorporated so that features in

66 We present the 97-gene signature as an accurate prognostic predictor of ov

67 ne signature changes ahead of the epithelial gene signature as prostate cancer initiates and progress

68 45% (changing area) to 1% of total 16S rRNA gene signatures as revealed via propidium monoazide trea

69 s) and defined a pluripotent cell fate (PCF) gene signature associated with acquisition of naive and

70 sis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, i

71 umor and OSE-derived cell lines reveal a 121 gene signature associated with EMT and metastasis.

72 nriched with E2F1 binding sites and define a gene signature associated with proliferative breast tumo

73 ive subtypes of prostate cancer and identify gene signatures associated with adverse clinical feature

74 hepatocellular carcinoma (HCC) to search for gene signatures associated with chromosomal instability

75 Gene signatures associated with IFNgamma and immune-medi

76 nts and molecular profiling, we identify the gene signatures associated with proliferation, different

77 We observed enrichment of gene signatures associated with several resistance drive

78 ponds with an increased incidence of ELS and gene signatures associated with their development and ac

79 ell proliferation and death, and to identify gene signatures associated with these effects.

80 ression analysis revealed an upregulation of gene signatures associated with transformation, prolifer

81 m based on subset-specific B-cell-associated gene signatures (BAGS) in the normal B-cell hierarchy, h

82 Here we present xCell, a novel gene signature-based method, and use it to infer 64 immu

83 Gene signature-based tumor microenvironment inference re

84 The "COXEN" method was utilized to filter gene signatures between human and dog datasets based on

85 However, a significant overlap of gene signatures between teams was observed for the major

86 ell types, and identified cell type specific gene signatures, bioprocesses, and key regulators.

87 5) as a key factor that regulates metastatic gene signatures both at the transcriptional and post-tra

88 early demonstrated that unfortunately the 13-gene signature cannot predict response to TP53-MDM2 inhi

89 g gene expression profiles, we established a gene-signature (CAV1, CD36, MLXIPL, CPT1C, CYP2E1) that

90 ational methodologies to produce a consensus gene signature (CGS).

91 ofiles in the prostate and show that stromal gene signature changes ahead of the epithelial gene sign

92 Interestingly, a day 1 gene signature characteristic of the innate response (an

93 ed with an epithelial-mesenchymal transition gene signature characteristic of transglutaminase 2/tran

94 rly and functionally distinct, with a unique gene signature characterized by expression of IL10 and I

95 press cell migration and stromal stimulation gene signatures compared with their SOX11(-) counterpart

96 H2 and Raji yielded an RCOR1 loss-associated gene signature comprising 233 genes.

97 Importantly, a PI3K SL gene signature containing the top hits of the SL genes i

98 In humans, a PMN gene signature correlated with improved survival in seve

99 rdingly, CASC15 levels correlated with known gene signatures corresponding to melanoma proliferative

100 MDSC-induced 'metastatic gene signature' derived from murine syngeneic model pred

101 d over time, and the relative impact of each gene signature differed between the investigated tissues

102 In addition, this microRNA-regulated gene signature differentiates sarcoidosis patients from

103 Z and expressed an immune activation-related gene signature distinct from that of circulating neutrop

104 we have shown that intrinsic and immune cell gene signatures distinguish the claudin-low subtype clin

105 The gene signature distinguishing IA from IT and IC patients

106 Akt3 was significantly correlated with a 76-gene signature DNA repair panel.

107 e progressive establishment of a HC-specific gene signature during in vitro iHC programming.

108 Finally, we showed that our BMI1-induced gene signature encompasses all of the hallmarks of the p

109 lly increases CA, and HIF-1alpha and hypoxic gene signature expression correlate with CA and centroso

110 expression correlate with CA and centrosomal gene signature expression in breast tumors.

111 ed with chemoresponse and to create a robust gene signature for follow-up studies.

112 iple, normal hepatic lineage stages reveal a gene signature for hFL-HCCs closely resembling that of b

113 re used to design a NET-related inflammatory gene signature for human myeloid malignancies.

114 The prognostic significance of the 233-gene signature for overall survival was reproduced in an

115 to show the prognostic value of the IMiD-14 gene signature for progression-free survival.

116 lyse a population spectrum, we highlight how gene signatures for LPS responsiveness can be derived ba

117 sed cancer profiles led to better prognostic gene signatures for lung and prostate cancer.

118 compendium of bioinformatics algorithms and gene signatures for molecular subtyping and prognosticat

119 ve defined a robust blood-derived type I IFN gene signature from MS patients.

120 ized procedure for constructing high quality gene signatures from a user's perspective.

121 ides an integrative approach to the study of gene signatures from multiple skin conditions, elucidati

122 positioning framework via incorporating drug-gene signatures from the Connectivity Map into the virus

123 cientists have discovered various prognostic gene signatures (GSs) in different cancer types.

124 inically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to pred

125 inically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to pred

126 The 3q gene signature had a strong association with features of

127 C from nIBC, but no IBC cancer-cell-specific gene signature has been identified.

128 r key component in this framework, the query gene signature, has been left to users to construct with

129 tients with a favorable immune and metabolic gene signature (high CD8A, high COX5B, low GLUT1) had im

130 en dementia and RNA quality, and find common gene signatures, highlighting the importance of properly

131 This BPDCN gene signature identified a dysregulation of genes invol

132 e prognostic and predictive value of a 3q 19-gene signature identified previously from lung cancer in

133 her dissection of the circulating tumor cell gene signature identified signaling pathways associated

134 The application of SAMS to the 52-gene signature identified two groups of patients with IP

135 s of the basal cell and two human small cell gene signatures identified a set of E2F target genes com

136 ome Atlas (TCGA) ovarian cancer dataset, the gene signature identifies a patient subset with decrease

137 We identified several gene signatures implicated in tumorigenesis of leukemia

138 e of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alte

139 g epithelial-to-mesenchymal transition (EMT) gene signature in a subset of cases that was attributabl

140 onal load was not correlated with a Th1/IFNG gene signature in any tumor type.

141 A proinflammatory NF-kappaB gene signature in CAFs has been suggested to promote tum

142 sion is negatively correlated with a hypoxic gene signature in glioblastoma patient samples, suggesti

143 thylation and expression of a TET2-dependent gene signature in human leukemia cell lines.

144 man macrophages, identify the MAFB-dependent gene signature in human macrophages and illustrate the c

145 RNA-sequencing analysis identified a unique gene signature in livers of Alb/AEG-1/c-Myc mice that wa

146 MP signaling maintained a trunk neural crest gene signature in melanomas.

147 oplasmic reticulum (ER) to Golgi trafficking gene signature in metastatic cells enhances transport ki

148 omic distribution analyses to define a STAT5 gene signature in natural killer (NK) cells, the prototy

149 We also identified a lipid metabolism gene signature in patients with TNBC that were identifie

150 ings demonstrate a decreased differentiation gene signature in PP/PN-KCs that had not been identified

151 The potential value of the 52-gene signature in predicting response to therapy should

152 We identified a HIF-2-dependent gene signature in sensitive tumours.

153 for tumour purity, we find an immunotherapy gene signature in several cancer types that is not detec

154 COPD, including drugs that reverse the COPD gene signature in silico.

155 monstrates that there is a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery

156 educe the severity of fibrosis or type I IFN gene signature in the skin.

157 creased mouse survival, and dampened the IFN gene signature in TREX1 mutant patient lymphoblasts.

158 tis confirmed the activation of a Jak1-STAT3 gene signature in vivo Together, our studies highlight J

159 Recent demonstrations of type I IFN gene signatures in autoimmune diseases, including sclero

160 significantly enriched in Imatinib response gene signatures in cell lines and chronic myelogenous le

161 expression profiling to define novel sets of gene signatures in human preadipocytes that could predic

162 We compared gene signatures in metastatic cells from tissues with lo

163 Significant differentially enriched gene signatures in patients with adult-onset as compared

164 We sought to investigate immune gene signatures in peripheral blood collected after NAC

165 orrelated with the eosinophil and neutrophil gene signatures in RD-SG patients, and with a B cell sig

166 ns indicate that NAMS is a robust prognostic gene signature, independent of other clinical and pathol

167 (ILC1s) from natural killer (NK) cells is a gene signature indicative of 'imprinting' by cytokines o

168 elop broader clinical relevance from disease gene signatures, Inkeles et al. demonstrate how mining p

169 ived neurons did not retain aging-associated gene signatures, iNs displayed age-specific transcriptio

170 Our study suggests that the 3q gene signature is a novel prognostic marker for lung and

171 y input to the connectivity mapping process, gene signature is crucially important in returning biolo

172 g evidence that high expression of stem cell gene signatures is associated with poor clinical outcome

173 pt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without

174 muM) significantly modulates the macrophage gene signature, lowers the expression of transcription f

175 Our results suggest that a novel four-gene signature may be used to increase sensitivity for P

176 The immune gene signatures may allow cross-sectional investigation

177 We named this assignment system the gene signature-MELD (gs-MELD) score.

178 taset to confirm its relationship to the SPC gene signature (n = 70) and determination of patient out

179 The gene signature of blood-derived TAMs, but not microglial

180 show that tumor-associated stroma mimics the gene signature of epithelial-to-mesenchymal transition (

181 Furthermore, a 33-gene signature of human orthologs was selectively enrich

182 In this study, we identified a gene signature of immature-like neutrophils, characteriz

183 kine levels, and non-classical monocytes; 3) gene signature of leukocyte activation and increased gra

184 In this study, we seek to identify a gene signature of metastatic melanoma.

185 A 16 gene signature of risk was identified.

186 ow report that a significant fraction of the gene signature of SZ hiPSC-derived neurons is conserved

187 The gene signature of this biomarker is highly supported by

188 , activation of the DNA damage response, and gene signatures of aggressive HCCs are observed.

189 In this study, we used gene signatures of CD40L stimulation derived from human

190 at evolutionarily conserved, stage-dependent gene signatures of early lung development are expressed

191 identify differentially enriched predefined gene signatures of leukocyte lineage, inflammatory and i

192 such concordance was found with the specific gene signatures of other histological types of breast ca

193 on of AIRE in vivo, we compared whole-genome gene signatures of purified mTEC subsets from TEC-specif

194 3 transcription factors (TF) associated with gene signatures of the known neuroendocrine/epithelial (

195 -kappaB, hereby switching on an inflammatory gene signature (p < 10(-16)).

196 platform-derived data, one of the six multi-gene signatures (P < 0.05) but no individual gene was as

197 HIV infection and that type I IFN-associated gene signatures persist, even during ART.

198 both TRIM24 protein levels and the AR/TRIM24 gene signature predict disease recurrence.

199 Stem cell gene signatures predict poor prognosis in AML patients;

200 ung adenocarcinomas, the presence of the 425-gene signature predicted a significantly shorter surviva

201 of treatment effect, we could not identify a gene signature predictive of clinical benefit to MAGE-A3

202 dent validation in 34 samples shows that the gene signature predicts RIF with 100% positive predictiv

203 In summary, we introduced a gene signature progression method into connectivity mapp

204 We introduce a "gene signature progression" method as a standard procedu

205 ational Prognostic Index low-risk group, the gene signature provides additional prognostic value that

206 the relationship between the RRS and the SPC gene signature (R = 0.45, P < .001, classification accur

207 The RRS scaled with the SPC gene signature (R = 0.57, P < .001, classification accur

208 from different joint locations and that HOX gene signatures reflect the joint-specific origins of mo

209 f two septic shock endotypes, based on a 100-gene signature reflecting adaptive immunity and glucocor

210 A stromal gene signature reflecting bone remodeling and immune-rel

211 The 25-gene signature reflects the abnormal development of stem

212 target genes, suggesting that the identified gene signature reflects the presence of at least a parti

213 dy, we identified mutant R132H IDH1-specific gene signatures regulated by key transcription factors,

214 ated by gene set variation analysis using 42 gene signatures relevant to asthma, inflammation, and im

215 w AMPK activation is linked to IL-4-elicited gene signatures remains unexplored.

216 ed were used to construct multiple non-joint gene signatures representing the same biological state.

217 We focus on gene signatures, representing highly enriched genes of i

218 This gene signature represents a promising prognostic biomark

219 Remarkably these non-joint gene signatures retrieved from connectivity mapping sepa

220 Pathway analysis of the 17-gene signature revealed Jak-STAT signaling pathway as th

221 is signature performs better than the random gene signatures selected from glioma-associated genes in

222 Functional pathways associated with gene signature sets were identified using the MetaCore a

223 is uncovered oxidative stress and DNA damage gene signatures significantly upregulated by AF-TUSC2-er

224 novel method of scoring each cell against a gene signature so as to minimize the effect of missed tr

225 We report a gene signature specific for human prostate basal cells t

226 7-deficient mice displays a cancer stem cell gene signature specified by the co-expression of ductal

227 lung cancer patients with an oncogenic KRAS gene signature, suggesting a novel candidate biomarker i

228 The 70-gene signature test (MammaPrint) has been shown to impro

229 ells from children exhibit less well-defined gene signatures than those in adults.

230 ve decreased up-regulation of HIF-associated gene signatures than white patients.

231 essively determine the minimum length of the gene signature that allows connections to the reference

232 Here we identify an HR defect (HRD) gene signature that can be used to functionally assess H

233 Here, we aim to establish a gene signature that can identify molecular pathways/tran

234 e have developed a prognostic G9a-suppressed gene signature that can stratify breast cancer patients.

235 on of CaMKK2 using RNA interference yields a gene signature that correlates with improvement in HCC p

236 ablished a new way to track Tregs by using a gene signature that discriminates between Tregs and conv

237 ce by transcriptional profiling may reveal a gene signature that identifies patients for whom immunos

238 Transcriptomic analyses generated a Notch gene signature that included Notch pathway components, t

239 In WT mice, exercise induces a gene signature that includes myofibrillar, mitochondrial

240 rs demonstrates elevated expression of a UPR gene signature that is a powerful new prognostic marker

241 By using this information, we identified a gene signature that is associated with patient survival

242 ssion analysis revealed that SREBP defines a gene signature that is associated with poor survival in

243 A SOMA for the CCRCC-specific SPC prognostic gene signature that is predictive of disease-specific su

244 and colleagues identify a p53-dependent six-gene signature that is specifically induced in hypoxia a

245 cytokine network and uncovered a blood-based gene signature that links psoriasis to other diseases of

246 We identified an 8-gene signature that predicted survival of patients with

247 tive polymerase chain reaction revealed a 45-gene signature that predicts overall survival (OS) in pa

248 T-cell subset was characterized by a unique gene signature that was related to that of CD4(+) T foll

249 myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2

250 or transcriptomic endotypes of asthma (TEA), gene signatures that discriminate phenotypes of disease.

251 mmune cell subsets and diseases based on the gene signatures that most differentiate them from other

252 Sequential pathogen exposure induced gene signatures that recapitulated those seen in blood f

253 As an alternative, we examine the use of gene signatures that rely on ranks from the data and sho

254 discovered a unique "circulating tumor cell gene signature" that is distinct from primary breast can

255 ere considered high risk according to the 90-gene signature; these patients had a higher rate of dise

256 BMP signaling in governing an embryonic cell gene signature to promote melanoma progression, thus pro

257 the use of this newly identified predictive gene signature to refine the selection of patients with

258 e clinical utility of the addition of the 70-gene signature to standard clinical-pathological criteri

259 of methylation and expression of SRD5A2 as a gene signature to tailor therapies for prostatic disease

260 We applied the dexamethasone-induced gene signature to The Cancer Genome Atlas glioblastoma d

261 Therefore, we link the cell-type-specific gene signatures to aggressive subtypes of prostate cance

262 ownstream genes of drug targets with disease gene signatures to display the potential therapeutic app

263 lge melanocyte precursors and compared their gene signatures to that of regenerated mature epidermal

264 pressing patients supported a cell migration gene signature underlying the mutant KRAS-mediated pheno

265 apigenin's effect, we next overlapped a 122-gene signature unique to HSCs with a list of 160 genes e

266 and hierarchical cluster analyses identified gene signatures unique to each population.

267 cribe a two-stage process for making quality gene signatures using gene expression data as initial in

268 /CREB-dependent anti-inflammatory and repair gene signature via the receptor TLR2.

269 In addition, the 3q gene signature was associated with better response to ne

270 a variety of cancers, downregulation of this gene signature was associated with poor clinical outcome

271 tion were upregulated at diagnosis, and this gene signature was associated with stricturing in the ri

272 Our gene signature was based on gene expression data from Ta

273 ncipal component (SPC) risk score prognostic gene signature was constructed and termed the radiogenom

274 In the metastatic subpopulations, a gene signature was defined (MET-75) that predicted survi

275 A 78-gene signature was defined for CAP, from which a FAIM3:P

276 The four-gene signature was found to be 91% accurate in a blinded

277 A 97-gene signature was identified as an independent predicto

278 When this gene signature was included, the model's specificity imp

279 A 52-gene signature was measured by the nCounter analysis sys

280 The 3q gene signature was strongly associated with lung metasta

281 Upregulation of an axon-guidance-related gene signature was the most significant feature of metas

282 Applying validated pathway-specific gene signatures, we detected a rapid and sustained downr

283 ntrols, while Th1, Th2, Treg, and eosinophil gene signatures were increased in patients without treat

284 Overlapping target gene signatures were observed in squamous cancer subsets

285 XBP1 target gene signatures were significantly induced in rodent liv

286 Responses in IR- or TH-associated gene signatures were tissue-specific and varied over tim

287 Literature-based gene signatures were used to evaluate the relative impac

288 pression of LncHIFCAR induces pseudo-hypoxic gene signature, whereas knockdown of LncHIFCAR impairs t

289 We demonstrate that results from existing gene signatures which rely on normalizing test data may

290 revealed the presence of the RPS14-deficient gene signature, which is associated with defective ribos

291 e Expression Omnibus to identify a robust 85-gene signature, which was used for computational drug re

292 hway in vivo reduced tumors and reversed the gene signature, which was verified in organotypic ex viv

293 The gene signature will be of value in counselling and guidi

294 a distinct activation of the IFN-stimulated gene signature with a substantial increase in the releas

295 In addition to sharing a gut-specific gene signature with memory IgA(+) B cells, memory IgM(+)

296 regulated in human cancers, but a Myc-driven gene signature with prognostic ability across multiple t

297 Compared to TH17 cells, TH1/17 cells have gene signatures with marked similarity to mouse pathogen

298 and gene set (four of the six reported multi-gene signatures with sufficient information for evaluati

299 g inflammatory chemokines, blunted antiviral gene signature within the pancreas, and reduced proinfla

300 Tumor ECs acquired the mesenchymal gene signature without the loss of EC functions, leading